Evidence map›Paper›PMID 24012110›Full record

Trial reportMolecular oncology2013

Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.

Ad J M Gillis, Martin A Rijlaarsdam, Ronak Eini, Lambert C J Dorssers, Katharina Biermann, Matthew J Murray, James C Nicholson, Nicholas Coleman, Klaus-Peter Dieckmann, Gazanfer Belge and 4 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Solid tumors of childhood display specific serum microRNA profiles.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Trial
  4. Trial
  5. Article
  6. Article
  7. Differences of sex development.Nature reviews. Disease primers · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Epigenetic Factors and ncRNAs in Testicular Cancer.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Ad J M GillisDepartment of Pathology, Erasmus MC - University Medical Center Rotterdam, Building Be, Room 432, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Martin A Rijlaarsdam
Ronak Eini
Lambert C J Dorssers
Katharina Biermann
Matthew J Murray
James C Nicholson
Nicholas Coleman
Klaus-Peter Dieckmann
Gazanfer Belge
Jörn Bullerdiek
Tom Xu
Nathalie Bernard
Leendert H J Looijenga
Erasmus MC · NLUniversity of Cambridge · GBLife Systems (United States) · USUniversity of Bremen · DE

Funding

Medical Research Council MC_U105359875
6 · The paper itself

Abstract

Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can consist of seminomas (SE) and non-seminomas (malignant NS: embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum-markers used for diagnosis and follow-up (AFP, hCG) are predominantly related to YS and CH and marker positivity can vary during disease. Therefore, stable markers consistently identifying more GCC components, specifically the stem cell components SE and EC, are of interest. Expression of the embryonic stem cell miR-371-3 and miR-302/367 clusters in SE/EC/YS suggest possible application of these micro-RNAs as GCC tumor-markers. The TSmiR protocol constitutes a complete, quality-controlled pipeline for the detection of miRs in serum, based on magnetic bead-based purification and qPCR quantification. As a proof of principle, TSmiR was applied to five independent serum sample series including 80 GCCs, 47 controls, 11 matched pre/post orchidectomy samples and 12 no-GCC testicular masses. GCC serum samples showed a consistent, significant (p < 0.0064) increase of miR-371/372/373/367 levels. Analogous, serum levels returned to baseline after orchidectomy (stage-I disease). Moreover, there was a trend toward higher miR levels in patients with metastasis. These results imply suitability for diagnosis and follow-up. TSmiR showed an overall sensitivity of 98%, clearly outperforming the traditional serum markers AFP/hCG (36%/57%, sensitivity(AFP) = 3%/45%; sensitivity(hCG) = 62%/66%, SE/NS). TSmiR misclassified one tumor as a control. Serum AFP/hCG and TSmiR combined identified all T samples correctly. In conclusion, TSmiR constitutes a highly sensitive and reproducible serum test for GCC patients, suitable to be prospectively tested for diagnostic and follow-up purposes.

Indexed as

AdolescentAdultBiomarkers, TumorChildChild, PreschoolHumansMaleMicroRNAsNeoplasms, Germ Cell and EmbryonalNeoplastic Stem CellsRNA, NeoplasmTesticular NeoplasmsBiomarkers, TumorMicroRNAsRNA, NeoplasmAFPGerm cell cancerhCGmiRNASerum markersTesticular cancer

Identifiers

PMID24012110
PMCPMC5528443
OpenAlexW2057950056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.